- Home
- CMPO vs DNLI Comparison
CMPO vs DNLI Comparison
Compare CMPO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- DNLI
- Stock Information
- Founded
- CMPO 2000
- DNLI 2013
- Country
- CMPO United States
- DNLI United States
- Employees
- CMPO N/A
- DNLI N/A
- Industry
- CMPO Finance: Consumer Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPO Finance
- DNLI Health Care
- Exchange
- CMPO Nasdaq
- DNLI Nasdaq
- Market Cap
- CMPO 2.0B
- DNLI 2.1B
- IPO Year
- CMPO N/A
- DNLI 2017
- Fundamental
- Price
- CMPO $19.41
- DNLI $13.26
- Analyst Decision
- CMPO Strong Buy
- DNLI Strong Buy
- Analyst Count
- CMPO 6
- DNLI 16
- Target Price
- CMPO $17.67
- DNLI $33.62
- AVG Volume (30 Days)
- CMPO 1.1M
- DNLI 2.0M
- Earning Date
- CMPO 11-07-2025
- DNLI 11-05-2025
- Dividend Yield
- CMPO N/A
- DNLI N/A
- EPS Growth
- CMPO N/A
- DNLI N/A
- EPS
- CMPO N/A
- DNLI N/A
- Revenue
- CMPO $267,817,999.00
- DNLI N/A
- Revenue This Year
- CMPO $10.30
- DNLI N/A
- Revenue Next Year
- CMPO $8.12
- DNLI $95,463.19
- P/E Ratio
- CMPO N/A
- DNLI N/A
- Revenue Growth
- CMPO N/A
- DNLI N/A
- 52 Week Low
- CMPO $9.24
- DNLI $10.57
- 52 Week High
- CMPO $20.14
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CMPO 61.12
- DNLI 35.14
- Support Level
- CMPO $19.14
- DNLI $14.63
- Resistance Level
- CMPO $19.65
- DNLI $15.69
- Average True Range (ATR)
- CMPO 0.67
- DNLI 0.73
- MACD
- CMPO -0.14
- DNLI -0.27
- Stochastic Oscillator
- CMPO 66.67
- DNLI 4.23
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.